-
公开(公告)号：WO2022197761A1
公开(公告)日：2022-09-22
申请号：PCT/US2022/020487
申请日：2022-03-16
申请人： MERCK SHARP & DOHME LLC , CERNAKA, Natalija , OGAWA, Anthony, K. , CHENG, Alan, C. , BAO, Jianming , SHARP, Phillip Patrick , LOPEZ, Jovan Alexander , XIAO, Dong , TANG, Haiqun
发明人： CERNAKA, Natalija , OGAWA, Anthony, K. , CHENG, Alan, C. , BAO, Jianming , SHARP, Phillip Patrick , LOPEZ, Jovan Alexander , XIAO, Dong , TANG, Haiqun
IPC分类号： A61K31/537 , C07D498/10 , A61P7/02 , A61P7/04
摘要： The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
-
公开(公告)号：WO2016015593A1
公开(公告)日：2016-02-04
申请号：PCT/CN2015/084937
申请日：2015-07-23
申请人： MERCK SHARP & DOHME CORP. , LIU, Weiguo , EDMONDSON, Scott D. , GUO, Zhuyan , SO, Sung-Sau , OGAWA, Anthony K. , KUANG, Rongze , WU, Heping , ALI, Amjad , GAO, Ying-Duo , JIANG, Yu , LI, Chunsing , YU, Tingting , PANDYA, Bhuamik , LIPPA, Blaise , ZHANG, Xin , BABER, Jon Christian , ROMERO, Jan Antoinette C. , ZHANG, Jing
发明人： LIU, Weiguo , EDMONDSON, Scott D. , GUO, Zhuyan , SO, Sung-Sau , OGAWA, Anthony K. , KUANG, Rongze , WU, Heping , ALI, Amjad , GAO, Ying-Duo , JIANG, Yu , LI, Chunsing , YU, Tingting , PANDYA, Bhuamik , LIPPA, Blaise , ZHANG, Xin , BABER, Jon Christian , ROMERO, Jan Antoinette C. , ZHANG, Jing
IPC分类号： C07D233/54 , C07D257/06 , C07D263/30 , C07D249/06 , C07D285/04 , C07D271/10 , A61K31/4164 , A61K31/4192 , A61K31/422 , A61K31/433 , A61P7/02
CPC分类号： C07D409/14 , A61P7/02 , C07D401/06 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
摘要翻译： 本发明提供式（I）化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓形成，栓塞，高凝状态或纤维化改变的方法。 这些化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽释放酶的双重抑制剂。
-
公开(公告)号：WO2007120574A2
公开(公告)日：2007-10-25
申请号：PCT/US2007/008583
申请日：2007-04-06
申请人： MERCK & CO., INC. , CHU, Lin , LI, Bing , OGAWA, Anthony, K. , OK, Hyun, O. , ONDEYKA, Debra, L. , PATEL, Minal , SISCO, Rosemary , UJJAINWALLA, Feroze , XU, Jinyou
发明人： CHU, Lin , LI, Bing , OGAWA, Anthony, K. , OK, Hyun, O. , ONDEYKA, Debra, L. , PATEL, Minal , SISCO, Rosemary , UJJAINWALLA, Feroze , XU, Jinyou
IPC分类号： C07D213/65 , C07D401/04 , C07D413/14 , C07D417/14 , A61K31/4412 , A61P29/00
CPC分类号： C07D213/65 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The instant invention provides compounds of Formula (II) which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (II) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
摘要翻译： 本发明提供了作为5-脂氧合酶活化蛋白抑制剂的式（II）化合物。 式（II）的化合物可用作抗动脉粥样硬化，抗哮喘，抗过敏，抗炎和细胞保护剂。
-
公开(公告)号：WO2006138163A3
公开(公告)日：2007-04-05
申请号：PCT/US2006022470
申请日：2006-06-09
IPC分类号： A61K31/7052 , A61P3/06 , A61P9/10 , C07D205/08 , C07H7/02 , C07H7/04
CPC分类号： C07D405/10 , C07D205/08 , C07H7/033 , C07H7/04 , C07H7/06 , C07H15/18 , C07H15/203
摘要： This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.
摘要翻译： 本发明提供式（I）的胆固醇吸收抑制剂及其药学上可接受的盐和酯。 该化合物可用于降低血浆胆固醇水平，特别是低密度脂蛋白胆固醇，以及治疗和预防动脉粥样硬化和动脉粥样硬化疾病事件。
-
公开(公告)号：WO2006044602A9
公开(公告)日：2006-06-08
申请号：PCT/US2005036940
申请日：2005-10-14
申请人： MERCK & CO INC , CHU LIN , KOPKA IHOR E , LI BING , OGAWA ANTHONY K , UJJAINWALLA FEROZE
发明人： CHU LIN , KOPKA IHOR E , LI BING , OGAWA ANTHONY K , UJJAINWALLA FEROZE
IPC分类号： C07D413/12 , A61K31/4439 , A61P9/10 , C07D213/30 , C07D401/12 , C07D401/14
CPC分类号： C07D213/30 , C07D401/12 , C07D401/14 , C07D413/12
摘要： The instant invention provides compounds of Formula (I), which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
摘要翻译： 本发明提供了式（I）的化合物，其是5-脂氧合酶活化蛋白抑制剂。 式（I）化合物可用作抗动脉粥样硬化剂，抗哮喘剂，抗过敏剂，抗炎剂和细胞保护剂。
-
公开(公告)号：WO2006044602A2
公开(公告)日：2006-04-27
申请号：PCT/US2005/036940
申请日：2005-10-14
申请人： MERCK & CO., INC. , CHU, Lin , KOPKA, Ihor, E. , LI, Bing , OGAWA, Anthony, K. , UJJAINWALLA, Feroze
发明人： CHU, Lin , KOPKA, Ihor, E. , LI, Bing , OGAWA, Anthony, K. , UJJAINWALLA, Feroze
IPC分类号： C07D413/12 , C07D401/12 , C07D401/14 , C07D213/30 , A61K31/4439 , A61P9/10
CPC分类号： C07D213/30 , C07D401/12 , C07D401/14 , C07D413/12
摘要： The instant invention provides compounds of Formula (I), which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
摘要翻译： 本发明提供了式（I）化合物，它是5-脂氧合酶活化蛋白抑制剂。 式（I）的化合物可用作抗动脉粥样硬化，抗哮喘，抗过敏，抗炎和细胞保护剂。
-
公开(公告)号：WO2006044602A3
公开(公告)日：2006-08-10
申请号：PCT/US2005036940
申请日：2005-10-14
申请人： MERCK & CO INC , CHU LIN , KOPKA IHOR E , LI BING , OGAWA ANTHONY K , UJJAINWALLA FEROZE
发明人： CHU LIN , KOPKA IHOR E , LI BING , OGAWA ANTHONY K , UJJAINWALLA FEROZE
IPC分类号： C07D413/12 , A61K31/4439 , A61P9/10 , C07D213/30 , C07D401/12 , C07D401/14
CPC分类号： C07D213/30 , C07D401/12 , C07D401/14 , C07D413/12
摘要： The instant invention provides compounds of Formula (I), which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
摘要翻译： 本发明提供了式（I）化合物，它是5-脂氧合酶活化蛋白抑制剂。 式（I）的化合物可用作抗动脉粥样硬化，抗哮喘，抗过敏，抗炎和细胞保护剂。
-
公开(公告)号：WO2015183709A1
公开(公告)日：2015-12-03
申请号：PCT/US2015/032091
申请日：2015-05-22
申请人： MERCK SHARP & DOHME CORP. , LIU, Weiguo , EDMONDSON, Scott, D. , GUO, Zhuyan , MERTZ, Eric , OGAWA, Anthony, K. , SO, Sung-Sau , SUN, Wanying , BROCKUNIER, Linda, L. , ALI, Amjad , KUANG, Rongze , WU, Heping
发明人： LIU, Weiguo , EDMONDSON, Scott, D. , GUO, Zhuyan , MERTZ, Eric , OGAWA, Anthony, K. , SO, Sung-Sau , SUN, Wanying , BROCKUNIER, Linda, L. , ALI, Amjad , KUANG, Rongze , WU, Heping
IPC分类号： A61K31/44 , A61K31/4192 , A61K31/167
CPC分类号： C07D417/10 , C07D213/89 , C07D401/10 , C07D401/12 , C07D401/14 , C07D413/10
摘要： The present invention provides a compound of Formula I(The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
摘要翻译： 本发明提供式I化合物（该化学式应在此插入）和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓形成，栓塞，高凝状态或纤维化改变的方法。 该化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽释放酶的双重抑制剂。
-
公开(公告)号：WO2020243049A1
公开(公告)日：2020-12-03
申请号：PCT/US2020/034468
申请日：2020-05-26
申请人： MERCK SHARP & DOHME CORP. , HICKS, Jacqueline, D. , DEBENHAM, John, S. , ALI, Amjad , WEI, Lan , JIAN, Tianying , YANG, Dexi , OGAWA, Anthony, K. , FU, Wenlang , LOMBARDO, Matthew , KUANG, Rongze , YANG, Meng , SO, Sung-Sau , ELLSWORTH, Kenneth , NIZNER, Peter , TATOSIAN, Daniel, A. , WILKENING, Robert, R. , WANG, Jun
发明人： HICKS, Jacqueline, D. , DEBENHAM, John, S. , ALI, Amjad , WEI, Lan , JIAN, Tianying , YANG, Dexi , OGAWA, Anthony, K. , FU, Wenlang , LOMBARDO, Matthew , KUANG, Rongze , YANG, Meng , SO, Sung-Sau , ELLSWORTH, Kenneth , NIZNER, Peter , TATOSIAN, Daniel, A. , WILKENING, Robert, R. , WANG, Jun
IPC分类号： A61K31/4162 , A61P7/02
摘要： The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.
-
公开(公告)号：WO2017095760A1
公开(公告)日：2017-06-08
申请号：PCT/US2016/063893
申请日：2016-11-29
申请人： MERCK SHARP & DOHME CORP. , OGAWA, Anthony, K. , BROCKUNIER, Linda, L. , TATA, James , PARKER, Dann, L., Jr. , WANG, Ming
IPC分类号： C07D213/00 , A61K31/44
CPC分类号： C07D409/14 , C07D401/10 , C07D401/14
摘要： The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
摘要翻译： 本发明提供了式I化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓形成，栓塞，高凝状态或纤维化改变的方法。 这些化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽释放酶的双重抑制剂。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.058 秒)
